-
04:13:30 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

INCY Stock News

08/26/22 10:00 AM
Nasdaq : INCY
fda approval
Incyte Announces FDA Approval of Pemazyre(R) (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
Incyte today announced that the U.S. Food and Drug Administration has approved Pemazyre (R), a selective fibroblast growth factor receptor inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. MLNs with FGFR1 rearrangement are extremely rare and aggressive blood cancers that may impact...
RHEA-AI
very positive
08/24/22 8:00 AM
Nasdaq : INCY
Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
Incyte today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2022 European Academy of Dermatology and Venereology Congress, held September 7-10, 2022, in Milan and virtually. "We are excited for the opportunity to present research from our growing dermatology portfolio at this year' s EADV...
RHEA-AI
positive
08/02/22 7:00 AM
Nasdaq : INCY
earnings
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Incyte today reports 2022 second quarter financial results, and provides a status update on the Company' s clinical development portfolio. Patient demand and satisfaction remain strong," said Herv? Hoppenot, Chief Executive Officer, Incyte." In July, Opzelura was also approved by the FDA in nonsegmental vitiligo, creating a new growth opportunity as the first...
RHEA-AI
positive
07/18/22 9:08 PM
Nasdaq : INCY
fda approval
Incyte Announces U.S. FDA Approval of Opzelura(TM) (ruxolitinib) Cream for the Treatment of Vitiligo
Incyte today announced that the U.S. Food and Drug Administration has approved Opzelura(TM) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Opzelura is the first and only FDA- approved treatment for repigmentation in patients with vitiligo, and the only topical formulation of a Janus kinase...
RHEA-AI
positive
06/13/22 4:01 PM
Nasdaq : MOR, PFE, INCY
clinical trial
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi(R) (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Pfizer Inc., MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG, and Incyte today announced a clinical trial collaboration and supply agreement to investigate the immunotherapeutic combination of Pfizer' s TTI-622, a novel SIRP?-Fc fusion protein, and Monjuvi (R) plus lenalidomide in patients with relapsed or...
RHEA-AI
positive
05/26/22 6:00 AM
Nasdaq : INCY
Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
Incyte today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 Congress. "We are committed to advancing science that can lead to solutions for patients with serious unmet medical needs, including those with cancer," said Steven Stein, M.D., Chief Medical...
RHEA-AI
neutral